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Abstract
I In nt tr ro od du uc ct ti io on n: :   Aim of this paper is to assess bone mineral density (BMD) and
body composition, by dual energy X-ray absorptiometry (DXA), and various
markers of bone growth, in a group of children with congenital adrenal
hyperplasia (CAH) on long-term glucocorticoid therapy.
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   A case-control study included thirty patients with CAH
with different states of metabolic control. Their mean age was 7.5 ±4.2 years.
All patients are subjected to BMD using DXA at the neck of the femur and
lumbar spine. A blood sample was taken for assessment of osteocalcin,
osteoprotegerin, and procollagen type 1, as markers of bone formation, as well
as RANKL and urinary deoxypyridinoline (DPD), as markers of bone resorption.
R Re es su ul lt ts s: :   We found no difference in BMD in patients and control subjects;
however, patients showed significantly lower serum osteocalcin (p = 0.008) 
and osteoprotegerin (p = 0.0001) and significantly higher serum RANKL levels
(p = 0.0001). Our results show that patients had significantly lower lean body
mass (p = 0.005) and fat/lean ratio (p = 0.008) compared to matched controls.
The duration of treatment showed a significant negative correlation with
procollagen type 1 (r = –0.49, p = 0.02) and lean mass % (r = –0.43, p = 0.04);
however, it showed a significant positive correlation with total fat mass % 
(r = 0.6, p = 0.0006), and fat/lean ratio (r = 0.43, p = 0.04). Dose of steroid had
a significant positive correlation with BMI SDS (r = 0.4, p = 0.02).
C Co on nc cl lu us si io on ns s: :   Bone mineral density is normal but bone turnover is low in patients
with CAH. There is an increase in fat/lean mass in patients with CAH.
K Ke ey y   w wo or rd ds s: :   dual energy X-ray absorptiometry, bone mineral density, osteocalcin,
osteoprotegerin, procollagen type 1.
Introduction
Children with congenital adrenal hyperplasia (CAH) receive glucocorticoid
therapy from the time of diagnosis, which may be at birth or even during
fetal life. There is evidence that even modern glucocorticoid replacement
therapy impacts on skeletal growth and maturation. Thus patients typically
show some degree of short stature and delayed bone maturation during
childhood [1].
In patients with CAH attributable to 21-hydroxylase deficiency, the
synthesis of cortisol (± aldosterone) is impaired. Consequently, the
secretion of ACTH is increased, resulting in excess androgen production.
Treatment of CAH consists of substitution of cortisol and aldosterone,
C Co or rr re es sp po on nd di in ng g   a au ut th ho or r: :
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thereby  preventing  an  adrenal  crisis  and
suppressing adrenal androgen overproduction [2].
Glucocorticoids must be dosed carefully to avoid
over-suppression (leading to growth retardation)
and under-suppression (leading to androgen excess
and reduction of final height) [3]. Glucocorticoid
administration, even in substitution doses, may
cause decreased bone mineral density (BMD) [4]
and obesity [5]. Previous reports on BMD in CAH
patients showed increased [6, 7], decreased [8-11],
or normal [12-14] BMD. These reports differed with
respect  to  age  selections  and  glucocorticoid
regimens. Body mass index (BMI) is found to be
elevated in most [8, 9, 11, 13, 15, 16], but not all 
[10, 14] reports on CAH patients, but it was not clear
whether this resulted from increased fat mass (as
a result of glucocorticoid treatment, despite the low
dose regimen) or increased lean mass (as a possible
result of androgen excess) [9, 10].
Bone  mass  measurement  defines  mineral
content per area of bone. In the laboratory, bone
density by DXA is a very strong predictor of bone
strength [17]. Biochemical markers of bone turnover
have been developed to look at bone metabolism.
They provide potentially useful information but
cannot be used alone to diagnose osteoporosis, to
determine the severity of the disease, or to select
a specific therapy. Urinary deoxypyridinoline (DPD)
and serum RANKL are markers of bone resorption,
while  osteocalcin,  osteoprotegerin,  and  serum
procollagen  I carboxyterminal  propeptide  are
markers of bone formation [18].
The aim of the current study was to assess BMD,
lean mass, and fat mass, by DXA, and various
markers of bone growth in a group of children with
CAH who have received long-term glucocorticoid
therapy under careful monitoring at our clinic.
Material and methods
It is a case-control study. Thirty patients with
CAH were recruited from the Paediatric Department
(Diabetes, Endocrine, and Metabolism Unit) at Cairo
University Paediatric Hospital. We also studied 
11 age- and sex-matched healthy controls who were
included in our study. All subjects were healthy and
appropriately physically active for their age; none
was  involved  in  competitive  sport  activities.
Candidates were excluded if they had a history of
chronic illness; they had one or more fractures; or
they had taken any medication, hormone, vitamin
preparation, or calcium supplements regularly. 
Inclusion criteria were patients with CAH on
treatment of more than 2 years’ duration and
exclusion criteria were newly diagnosed patients or
treatment duration less than 2 years. The study
included 27 patients with classic 21-hydroxylase
deficiency,  one  patient  with  simple  virilizing 
21-hydroxylase deficiency and 2 patients with 3β
hydroxysteroid dehydrogenase deficiency. Twenty-
four patients were diagnosed in the first year of life.
The remaining 6 were diagnosed at the age of 2-9
years; they were simple virilizing 21 OH deficiencies,
late  onset  3β hydroxysteroid  dehydrogenase
deficiency, and late diagnosis of the classic forms. All
had been treated from the onset of diagnosis with
glucocorticoids and mineralocorticoids in salt losing
forms or glucocorticoid in simple virilizing forms.
All patients were followed up regularly with
biochemical,  hormonal,  and  anthropometric
measurements. The following data were obtained
for patients and controls: age at diagnosis and start
of therapy, duration of treatment, dose of glu-
cocorticoid and mineralocorticoid for patients only,
height and weight measured with a stadiometer
and a clinical scale at the time of examination, body
mass index (BMI) calculated as kilograms per metre
squared, height SDS and weight SDS calculated
with a growth calculator as previously described
[19], BMI SDS expressed with data published by
Cole  et  al.  [20],  pubertal  assessment,  LHRH-
analogue treatment for patients only, and bone age
assessed  by  X-ray  of  the  left  hand  using  the
Greulich and Pyle method [21]. 
In the 21-hydroxylase deficient subjects, tight
control  was  defined  as  a mean  serum  170H-
progesterone value of all clinic visits of less than 
10 nmol/l, fair control was defined as a mean serum
170H-progesterone value of 10-40 nmol/l, together
with normal levels of plasma rennin, and poor control
was defined as a mean serum 170H-progesterone
value over 40 nmol/l [22]; these were noncompliant
patients who also showed elevated levels of serum
testosterone and plasma rennin [1]. The 2 patients
with 3β-hydroxysteroid dehydrogenase deficiency
were tightly controlled since their DHEA was below
5 nmol/l and normal plasma renin activity. All enrolled
patients and controls were subjected (after their
verbal consent) to:
1) bone mineral content (BMC, g), areal BMD (BMD,
g/cm2), fat mass, and lean mass were assessed
by DXA (Norland – XR- 46, USA) at the lumbar
spine (L1–L4) and the right femoral neck; absolute
values were converted to Z-scores (standard
deviations from the mean of a healthy age- and
sex-matched reference population);
2) blood  samples  were  collected  by  clean
venipuncture into Vacutainer plane tubes under
strict sterile conditions; 5 ml of venous blood was
obtained and put into a water bath for 15 min
and  centrifuged  at  4000  rpm;  serum  was
separated and kept at –20°C for estimation of
the different hormonal profiles as well as the
following bone markers:
a) osteocalcin,  using  –  ELISA  kit  (Biosource,
Europe, S.A.) which is a quantitative sandwich
enzyme-linked immunosorbent assay,
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b) serum osteoprotegerin using ELISA technique
(Biovendor Laboratory Medicine, Inc., Czech
Republic), Cat. No. RD 194003200; it is a biotin
labelled antibody based sandwich enzyme
immunoassay,
c) procollagen  type  1  using  Metra  CICP 
assay;  it  is  a sandwich  enzyme  immuno-
assay in a microtitre plate format utilizing
a monoclonal anti-CICP antibody coated on
the plate, a rabbit anti-CICP antiserum, a goat
anti-rabbit alkaline phosphatase conjugate,
and substrate to quantify the CICP in human
serum,
d) serum  RANKL  levels  by  using  ELISA  kit,
Biomedica  group,  Biomedica  Medicine
product,  GmbH  and  Co;  it  is  an  enzyme
immunoassay  for  the  quantitative  deter-
mination of sRANKL in serum Cat. No. Bl –
20422 H,
e) serum  testosterone  was  measured  by
chemiluminescence enzyme immunoassay
(Immulite  2000  Diagnostic  Products  Los
Angeles, CA, USA),
f) serum 17 OH was measured by ELISA kit DRG
(Germany) cat. no. EIA 1292 and it is based on
the competition principle and micro-plate
separation,
g) Delta  4  androstenedione,  dehydroepian-
drostenedione DHEA, and plasma renin were
measured by Radioimmunoassay cat. no. IT
1322 Cis. Bioassay 30200 Bagnols/CIZA France;
the procedure follows the basic principle of
RIA, where there is competition between
radioactive and non-radioactive antigen for
a fixed number of antibody binding sites; the
amount of 1.25 labelled antigen bound to the
antibody is inversely proportional to their
concentration; separation of the free and the
bound antigen is achieved by decanting or
aspirating the coated tubes;
3) urinary deoxypyridinoline (DPD) using Metra EIA
DPD assay Cat. no. 8007; it was carried out by
using preservative first morning void urine or
secondary morning void urine; metra DPD assay
is  a competitive  enzyme  immunoassay  in
microtitre strip-well format utilizing a monoclonal
anti-DPD antibody coated on the strip to capture
DPD;  DPD  in  the  sample  competes  with
conjugated  DPD  alkaline  phosphatase  for
antibody  and  the  reaction  is  detected  with
substrate; metra DPD results are corrected for
urinary concentration by creatinine in urine.
S St ta at ti is st ti ic ca al l   a an na al ly ys si is s
Statistical Package for the Social Sciences (SPSS)
program version 9.0 was used for analysis of data.
Data were summarized as mean and SD. Non-
parametric tests were used: Mann-Whitney U test
was used for analysis of 2 quantitative data and
Kruskal-Wallis U test for comparison of more than
2 quantitative variables. Friedman ANOVA was used
to compare between the three groups of 21-hy-
droxylase deficiency patients (tight, fair, and poor
control)  and  different  parameters.  Spearman
correlation was done when appropriate.
Results
D De es sc cr ri ip pt ti iv ve e   d da at ta a   o of f   t th he e   s st tu ud dy y   g gr ro ou up p   
Thirty patients with CAH were included in the
study, mean age 7.5 ±4.2 (range 3-18 years). Twenty-
two  were  females  and  8  were  males.  Among
patients with 21-OH deficiency, 16 patients were on
tight  control  (mean  17-OHP  2.4  ±2.3  nmol/l), 
9  patients  showed  fair  control  (mean  17-OHP 
15.4 ±2.4 nmol/l, normal PRA), and 3 patients
showed bad control due to non-compliance (mean
17-OHP 47 ±4.3 nmol/l, high PRA). Two patients
with 3β hydroxysteroid dehydrogenase deficiency
were on tight control. Three of our patients received
LHRH analogue due to central precocious puberty
(1  with  fair  control  and  2  with  bad  control).
Descriptive data of the study group including their
biochemical bone markers, body composition, and
DXA results are shown in Table I.
C Co om mp pa ar ri is so on n   b be et tw we ee en n   p pa at ti ie en nt ts s   a an nd d   c co on nt tr ro ol l
s su ub bj je ec ct ts s   
Patients included in the study showed significant
lower lean body mass and higher total fat mass,
abdomen fat %, trunk fat %, soft tissue fat mass %
and fat/lean ratio compared to matched controls
(Table II). Also, our patients showed significantly
lower serum osteocalcin and osteoprotegerin, and
significantly higher serum RANKL levels.
E Ef ff fe ec ct t   o of f   p pu ub be er rt ty y, ,   g ge en nd de er r, ,   c co on nt tr ro ol l   s st ta at te e, ,   a an nd d
t tr re ea at tm me en nt t   w wi it th h   L LH HR RH H   a an na al lo og gu ue e   
Our data showed no significant differences
between pre-pubertal (n = 9) and pubertal (n = 21)
patients regarding their biochemical bone markers
and DXA parameters except for BMC, which is
higher in the pubertal group than in the prepubertal
group  (1259.1  ±399.5 g  and  840.3  ±458  g,
respectively, p = 0.05). Moreover, no significant
difference  was  found  between  patients  who
received  LHRH  analogue  and  the  rest  of  the
patients in any of the DXA parameters or bone
turnover markers. Our results show no significant
differences between the three groups with different
control state as well as between male and female
patients regarding their biochemical markers and
DXA results.
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M Me ea an n   ± ±   S SD D M Mi in ni im mu um m    M Ma ax xi im mu um m   
A Ag ge e   a at t   s st ta ar rt t   o of f   t th he er ra ap py y   [ [y ye ea ar rs s] ] 1.86 ±4.13 0.1 9
D Du ur ra at ti io on n   o of f   t tr re ea at tm me en nt t   [ [y ye ea ar rs s] ] 6.47 ±3.13 2.4 14
A Av ve er ra ag ge e   d do os se e   o of f   g gl lu uc co oc co or rt ti ic co oi id ds s   [ [m mg g/ /M M2 2/ /d da ay y] ] 15.5 ±3.68 5 21.5
D Do os se e   o of f   m mi in ne er ra al lo oc co or rt ti ic co oi id d   [ [µ µg g/ /d da ay y] ] 0.11 ±4.1-02 0.05 0.2
H He ei ig gh ht t   S SD DS S –0.58 ±1.58 –3.7 2.3
W We ei ig gh ht t   S SD DS S 7.14-03 ±1.79 –3 3.2
B BM MI I   S SD DS S 0.59 ±1.6 –3.2 3
P Pr ro oc co ol ll la ag ge en n   t ty yp pe e   1 1   [ [n ng g/ /m ml l] ] 325 ±150.8 79 716
O Os st te eo oc ca al lc ci in n   [ [n ng g/ /m ml l] ] 21.1 ±28.1 0.1 75
O Os st te eo op pr ro ot te eg ge er ri in n   [ [p pg g/ /l l] ] 1.99 ±0.99 0.3 3.6
D De eo ox xy yp py yr ri id di in no ol li in ne e   [ [n nm mo ol l/ /m mm mo ol l   c cr re ea at ti in ni in ne e] ] 62.45 ±67 1.13 285
R RA AN NK KL L   [ [p pm mo ol l/ /l l] ] 116.98 ±72.43 40 290
B BM MD D   t to ot ta al l   [ [g gm m/ /c cm m3 3] ] 0.64 ±9.9-2 0.44 0.83
B BM MC C   t to ot ta al l   [ [g gm m] ] 1144.86 ±447.6 468 1954
F Fe em mu ur r   Z Z- -s sc co or re e –0.184 ±0.66 –1.28 0.9
V Ve er rt te eb br ra al l   Z Z- -s sc co or re e 0.28 ±0.76 –0.89 1.86
T To ot ta al l   f fa at t   [ [% %] ] 32.77 ±10.1 12 47
L Le ea an n   m ma as ss s   [ [% %] ] 65.93 ±10.44 51.25 87.28
L Le ea an n/ /f fa at t   r ra at ti io o 0.55 ±0.24 0.15 0.95
F Fa at t/ /l le ea an n   r ra at ti io o 2.33 ±1.46 1.1 6.86
T Tr ru un nk k   f fa at t   [ [% %] ] 28.2 ±3.34 22.8 38.12
A Ab bd do om me en n   f fa at t   [ [% %] ] 16.5 ±3.89 8.19 25.77
S So of ft t   t ti is ss su ue e   [ [% %] ] 34.1 ±10.44 12.72 48.75
T Ta ab bl le e   I I. . Descriptive data of the study population
P Pa at ti ie en nt ts s   ( (n n = =   3 30 0) ) C Co on nt tr ro ol ls s   ( (n n = =   1 11 1) ) P P- -v va al lu ue e
B BM MD D   [ [g gm m/ /c cm m3 3] ] 0.64 ±1 0.6 ±0.02 0.05
B BM MC C   [ [g gm m] ] 1144.0 ±447.6 585.8 ±149.9 0.06
L Le ea an n   m ma as ss s   [ [% %] ] 65.9 ±10.4 76.1 ±5.6 0.005
F Fa at t   m ma as ss s   [ [% %] ] 32.8 ±10.1 22.5 ±5.6 0.006
A Ab bd do om me en n   f fa at t   [ [% %] ] 16.5 ±3.9 13 ±5.1 0.03
T Tr ru un nk k   f fa at t   [ [% %] ] 28.2 ±3.3 21.6 ±8.3 0.003
S So of ft t   t ti is ss su ue e   m ma as ss s   [ [% %] ] 34.1 ±10.4 23.9 ±5.6 0.005
F Fa at t/ /l le ea an n   r ra at ti io o 0.6 ±0.2 0.3 ±1 0.008
L Le ea an n/ /f fa at t   r ra at ti io o 2.3 ±1.5 3.4 ±1.2 0.008
O Os st te eo oc ca al lc ci in n   [ [n ng g/ /m ml l] ] 21.1 ±28.1 49.4 ±34.5 0.008
O Os st te eo op pr ro ot te eg ge er ri in n   [ [p pg g/ /l l] ] 2 ±1 30.9 ±33 0.0001
P Pr ro oc co ol ll la ag ge en n   t ty yp pe e   1 1   [ [n ng g/ /m ml l] ] 325 ±150.8 376 ±218.5 0.4
D De eo ox xy yp py yr ri id di in no ol li in ne e   [ [n nm mo ol l/ /m mm mo ol l   c cr re ea at ti in ni in ne e] ] 62.4 ±67 60.8 ±33.6 0.3
R RA AN NK KL L   [ [p pm mo ol l/ /l l] ] 117 ±72.4 19.5 ±3.7 0.0001
T Ta ab bl le e   I II I. .   Comparison between patients and control subjects
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E Ef ff fe ec ct t   o of f   d du ur ra at ti io on n   a an nd d   d do os se e   o of f   s st te er ro oi id d   t tr re ea at tm me en nt t
In our study, the duration of treatment showed
a significant negative correlation with procollagen
type 1 (r= –0.49, p= 0.02) (Figure 1) and lean mass %
(r =  –0.43,  p =  0.04).  However,  it  showed
a significant positive correlation with abdomen fat %
(r =  0.6,  p =  0.006),  soft  tissue  %  (r =  0.43, 
p = 0.04), total fat mass % (r = 0.43, p = 0.04), and
fat/lean ratio (r = 0.43, p = 0.04) (Figure 2). Dose of
steroid showed a significant positive correlation
with BMI SDS (r = 0.4, p = 0.02).
C Co or rr re el la at ti io on n   b be et tw we ee en n   B BM MI I, ,   b bi io oc ch he em mi ic ca al l   b bo on ne e
m ma ar rk ke er rs s, ,   a an nd d   D DX XA A   p pa ar ra am me et te er rs s   
BMI  SDS  showed  a significant  positive
correlation with total fat % (r = 0.7, p = 0.001),
fat/lean ratio (r = 0.72, p = 0.0001), and soft tissue %
(r = 0.7, p = 0.0001). Accordingly, BMI SDS showed
a negative  correlation  with  lean  mass  % 
(r = –07, p =0.0001) and lean/fat ratio (r = –0.6, 
p =  0.004).  Bone  mineral  density  was  not
diminished in the distal femur (femur Z-score = 
–0.184 ±0.66) and lumbar spine (vertebral Z-score
= 0.28 ±0.76). No correlation was found between
biochemical bone markers and any of the DXA
parameters except for osteoprotegerin, a marker of
bone  formation,  which  showed  a positive
correlation with femur Z-score (r = 1, p = 0.00001)
and vertebral Z-score (r = 1, p = 0.00001).
Discussion
In children with congenital adrenal hyperplasia,
concerns have been raised that glucocorticoid
replacement therapy might reduce growth and final
height and might predispose to later osteoporosis
[2, 16]. In this study, we have shown that children
and adolescents with CAH on long-term steroid
therapy  have  normal  bone  mineral  density;
however,  they  have  low  serum  osteocalcin,
osteoprotegerin, and procollagen peptide of type 1
collagen and high serum RANKL levels, i.e. our
patients have low bone formation markers and high
bone resorption markers (Table II). We have found
that vertebral Z-scores of our patients, which is
a sensitive indicator to the effect of steroid therapy
[23], are considered normal according to the World
Health Organization [24]. Normal BMD in CAH
patients has been reported earlier by other authors
[13, 25, 26], who found that adolescents with CAH
had BMD values comparable with controls, despite
glucocorticoid  treatment.  These  authors
hypothesized  that  negative  effects  of  gluco-
corticoids on bone could be balanced by positive
effects of androgens. Evidently, this may be true as
long as glucocorticoid doses in CAH patients are in
the low currently suggested dose [27]. Although our
patients have low bone turnover, they have normal
BMD. The normal bone status may be explained by
the differential effects of glucocorticoids on growing
bone,  beneficial  androgen  effects,  and  other
disease-specific factors [25]. The normal BMD that
we observed in our patients does not rule out that
these patients may develop glucocorticoid-induced
osteoporosis at an older age. Lower lumbar and
femoral neck BMD scores than controls were found
in patients who had completed puberty [9]. As
regards  the  bone  turnover  markers  and  their
relation to BMD, our data are in agreement with
Guo et al. [12], who found that BMD was not
significantly decreased and that bone turnover was
decreased  in  congenital  adrenal  hyperplasia
patients.  However,  they  measured  serum
osteocalcin and bone alkaline phosphatase to
assess bone formation, whereas serum tartrate-
resistant acid phosphatase and urinary cross-linked
N-telopeptides of type I collagen were used to
assess bone resorption. Also Sciannamblo et al. [28]
found that bone resorption markers were higher in
patients with CAH.
In our clinic a protocol of regular monitoring of
steroid dose, growth, serum 170H-progesterone,
testosterone,  and  plasma  renin  activity  were
followed. The average dose of hydrocortisone and
mineralocorticoid was 15.5 ±3.68 mg/M2/day and
0.11 ±4.1-02 µg/day, respectively. Although we had
patients with different control states as previously
mentioned, no significant difference between these
groups  regarding  their  BMD,  BMC,  body
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composition,  and  bone  turnover  markers  was
found. Moreover, the dose of steroid replacement
did not show any significant relation to BMD or
BMC or any of the bone turnover markers. Girgis
and Winter [1] found no significant difference
between the three groups of metabolic control
(tight, fair, and bad) regarding their vertebral BMD
and serum osteocalcin, procollagen peptide, or
collagen C-terminal telopeptide, or in urinary amino-
terminal telopeptide. Mora et al. [13], Fleischman 
et al. [25], and Sciannamblo et al. [28] found that
BMD measurements and bone turnover markers
did not correlate with actual glucocorticoid dose or
mean dose over the previous 7 years, which is
consistent  with  our  results.  However,  when
glucocorticoids are given at higher doses, this will
cause increased bone resorption and inhibition of
bone formation, leading to reduced BMD. Previous
reports showed that decreased BMD in adult CAH
patients  was  associated  with  glucocorticoid
overdosing [9, 10]. Bachelot et al. [29] found that
hydrocortisone dose was negatively correlated with
the BMD T-score at the femoral neck.
As in earlier studies, we found that BMI was
significantly higher in CAH patients compared with
controls [10, 21, 29]. As regards body composition,
our  patients  showed  higher  fat  content  than
controls, which is related to the dose of steroid and
duration of treatment. The increased fat mass could
be the result of glucocorticoid use; other possible
explanations for the increased fat mass could be
adrenomedullary  dysfunction  with  decreased
catecholamine secretion, as recently described in
CAH patients. Additionally, children with CAH had
increased  leptin  levels  and  decreased  insulin
sensitivity,  which  has  been  ascribed  to  their
adrenomedullary dysfunction.
In conclusion, children and adolescents with
congenital adrenal hyperplasia have low bone
turnover, normal BMD, high body fat content, and
low lean mass. We recommend follow-up of the
bone mineral density of these patients as they
might be predisposed to later osteoporosis. In
addition, we recommend further studies to clarify
the role of calcium supplementation in CAH patients
and study the diet provided to these patients to
avoid overweight and obesity.
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